Kynam Capital Management, LP
PRINCETON, NJ · CIK 1907884 · 13F filing filed 2025-08-14
SEC-registered investment adviser since 2022 · limited partnership
- Assets managed$2.4bn
- Staff3 · 2 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $2.4bn gross assets
- Form ADV · 2026-04-10SEC adviser record
- Legal entityKYNAM CAPITAL MANAGEMENT, LP (US)
- Kindhedge funds, futures
- Others nearbyPrinceton, NJ
As an employer
- Private fundshedge 1
$928.8m
reported value
-20.5% vs Q1 2025
31positions
77.4%in top 10
3 new
4 added
21 reduced
3 sold out
vs Q1 2025
Holdings, Q2 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| CELLDEX THERAPEUTICS INC NEW CLDX | $124.1m13.37% | Reduced -399.3k |
| VAXCYTE INC PCVX | $99.9m10.75% | Reduced -128.4k |
| VERA THERAPEUTICS INC VERA | $80.7m8.69% | Added +1.0m |
| SYNDAX PHARMACEUTICALS INC SNDX | $79.8m8.59% | Unchanged |
| BIOCRYST PHARMACEUTICALS INC BCRX | $75.8m8.16% | Reduced -464.8k |
| CG ONCOLOGY INC CGON | $63.9m6.88% | Reduced -154.0k |
| VIRIDIAN THERAPEUTICS INC VRDN | $61.9m6.66% | Reduced -272.1k |
| COGENT BIOSCIENCES INC COGT | $61.0m6.56% | Reduced -612.4k |
| BEAM THERAPEUTICS INC BEAM | $41.1m4.43% | Reduced -100.5k |
| IMMUNOCORE HLDGS PLC IMCR | $30.6m3.30% | Reduced -719.3k |
| WAVE LIFE SCIENCES LTD 96663EUR | $29.6m3.19% | Reduced -339.4k |
| TRAVERE THERAPEUTICS INC TVTX | $22.8m2.45% | Reduced -262.1k |
| TYRA BIOSCIENCES INC TYRA | $22.3m2.40% | Reduced -76.1k |
| DYNAVAX TECHNOLOGIES CORP DVAX | $21.3m2.29% | Reduced -475.5k |
| ENGENE HOLDINGS INC COM | $18.2m1.96% | Unchanged |
| CULLINAN THERAPEUTICS INC CGEM | $15.8m1.70% | Reduced -242.6k |
| NURIX THERAPEUTICS INC NRIX | $13.4m1.44% | Added +373.6k |
| RELAY THERAPEUTICS INC RLAY | $10.0m1.08% | Reduced -176.3k |
| AMARIN CORP PLC AMRN | $9.3m1.01% | New |
| UROGEN PHARMA LTD URGN | $9.0m0.97% | Added +631.6k |
| CYTOMX THERAPEUTICS INC CTMX | $4.9m0.53% | New |
| GERON CORP GERN | $4.9m0.52% | Reduced -203.2k |
| IRONWOOD PHARMACEUTICALS INC IRWD | $3.9m0.42% | Reduced -356.1k |
| CARIBOU BIOSCIENCES INC CRBU | $3.9m0.42% | Reduced -201.4k |
| SUTRO BIOPHARMA INC COM | $3.6m0.39% | Reduced -353.3k |
| DESIGN THERAPEUTICS INC DSGN | $3.5m0.37% | Added +125.6k |
| PROQR THRAPEUTICS N V PRQR | $3.4m0.36% | Reduced -100.5k |
| EDGEWISE THERAPEUTICS INC EWTX | $3.3m0.36% | New |
| BURNING ROCK BIOTECH LTD BNR | $3.1m0.34% | Unchanged |
| LIQUIDIA CORPORATION LQDA | $2.5m0.27% | Reduced -433.8k |
| CLIMB BIO INC CLYM | $1.3m0.14% | Reduced -18.7k |
Sold out since Q1 2025
| Security | Value then |
|---|---|
| NATERA INC NTRA | $165.1m1.2m shares |
| LEGEND BIOTECH CORP LEGN | $20.7m610.0k shares |
| AMARIN CORP PLC | $5.6m12.4m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| BURNING ROCK BIOTECH LTD 13G · filed 2026-05-15 | 14.0% |
| SYNDAX PHARMACEUTICALS INC SNDX · 13G · filed 2025-02-14 | 10.0%≈ $186.2m |
| CYTOMX THERAPEUTICS INC CTMX · 13G · filed 2026-08-14 | 10.0% |
| CELLDEX THERAPEUTICS INC NEW CLDX · 13G · filed 2026-08-14 | 6.8% |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 5.7% |
| SUTRO BIOPHARMA INC 13G · filed 2026-05-15 | 5.3% |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2026-03-04 | 5.3%≈ $56.7m |